Cell populations which co-express CD49c and CD90
AssigneeNeuronyx, Inc.
InventorsTony Ho, Gene Kopen, William Righter, J. Rutkowski, Joseph Wagner
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeuronyx, Inc.
InventorsTony Ho, Gene Kopen, William Righter, J. Rutkowski, Joseph Wagner
Estimating the term…
Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.
A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
Dependencies are inferred from the claim text.